ARS Pharmaceuticals Stock
ARS Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Donn Casale
- Employees
- 195
- Market cap
- $400 M
- IPO
- 04/12/2020
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or…
ARS Pharmaceuticals stock: price history
1D
-1.2%
1W
-5.0%
1M
-3.6%
6M
-50.9%
YTD
-65.5%
1Y
-60.2%
2Y
-75.7%
5Y
-59.2%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~38% stronger price swings than usual
Ask the agents about ARS Pharmaceuticals
Analyst assessment of ARS Pharmaceuticals
PRICE TARGET LOW
US$15.00
CONSENSUS
US$15.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$15.00
1
STRONG BUY
3
BUY
6
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Hold
As of: 13/08/2026
ARS Pharmaceuticals stock metrics
P/E
-1.84
P/B
31.91
EV/EBITDA
-2.72
RETURN ON EQUITY
-498.2%
NET MARGIN
-185.2%
DEBT/EQUITY
13.72
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
65.6%
FLOAT SHARES
65,253,639
AVG. DAILY VOLUME (30D)
1,532,191
Insider transactions (SEC)
Fitzpatrick Alexander A
Karas Eric
Karas Eric
Institutional holders
Comparable stocks
Frequently asked questions about ARS Pharmaceuticals stock
What does ARS Pharmaceuticals do?
ARS Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Donn Casale, the company employs around 195 people.
The IPO was on 04/12/2020; the stock trades on NASDAQ under the ticker SPRY.
What do analysts say about ARS Pharmaceuticals stock?
10 analysts rate the stock, the consensus is Hold (as of 13/08/2026).
The average price target is US$15.00, ranging from US$15.00 to US$15.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does ARS Pharmaceuticals report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 38% stronger than usual.
Does ARS Pharmaceuticals pay a dividend?
No, ARS Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to ARS Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get ARS Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess ARS Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.